Michael S. Briley

Michael S. Briley's AcademicInfluence.com Rankings

Michael S. Briley

Psychology

#2740

World Rank

#3153

Historical Rank

Behavioral Neuroscience

#26

World Rank

#27

Historical Rank

psychology Degrees

Michael S. Briley

Biology

#8547

World Rank

#11643

Historical Rank

Neuroscience

#1185

World Rank

#1228

Historical Rank

biology Degrees

Download Badge

Psychology
Biology

Michael S. Briley's Degrees

PhD Neuroscience Stanford University

Why Is Michael S. Briley Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Michael S. Briley's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Validation of open : closed arm entries in an elevated plus-maze as a measure of anxiety in the rat (1985) (5422)
The increasing burden of depression (2011) (915)
SNRIs: The Pharmacology, Clinical Efficacy, and Tolerability in Comparison with Other Classes of Antidepressants (2005) (439)
Tritiated imipramine binding sites are decreased in platelets of untreated depressed patients. (1980) (430)
High-affinity [3H]imipramine binding in rat hypothalamus: association with uptake of serotonin but not of norepinephrine. (1980) (361)
Animal models of anxiety: the effect of compounds that modify 5-HT neurotransmission (1987) (282)
The importance of norepinephrine in depression (2011) (272)
Specific tricyclic antidepressant binding sites in rat brain (1979) (266)
The epidemiology of pain in depression (2004) (256)
Human platelets possess high-affinity binding sites for 3H-imipramine. (1979) (237)
Specific tricyclic antidepressant binding sites in rat brain characterised by high-affinity 3H-imipramine binding. (1980) (223)
Neurobiological mechanisms involved in antidepressant therapies. (1993) (197)
Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug (1985) (170)
New concepts in anxiety (1990) (161)
Localisation of Tricyclic Antidepressant Binding Sites on Serotonin Nerve Terminals (1981) (148)
High-affinity binding of 3H-imipramine in brain and platelets and its relevance to the biochemistry of affective disorders. (1981) (142)
Inhibition of androgen metabolism and binding by a liposterolic extract of "Serenoa repens B" in human foreskin fibroblasts. (1984) (141)
Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability (1997) (133)
Characterization of dopamine autoreceptor and [3H]spiperone binding sites in vitro with classical and novel dopamine receptor agonists. (1983) (127)
Understanding pain in depression (2004) (127)
Influence of GABA receptor agonists and antagonists on the binding of 3H-diazepam to the benzodiazepine receptor. (1978) (121)
High-affinity 3H-imipramine binding in rat cerebral cortex. (1979) (119)
The possible role of 5-HT(1B/D) receptors in psychiatric disorders and their potential as a target for therapy. (2000) (117)
High-affinity [3H]desipramine binding in the peripheral and central nervous system: a specific site associated with the neuronal uptake of noradrenaline. (1982) (112)
Binding of Permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostate. (1984) (109)
Reduced uptake of serotonin but unchanged 3H-imipramine binding in the platelets from cirrhotic patients. (1981) (106)
Distribution of Specific High‐Affinity Binding Sites for [3H]Imipramine in Human Brain (1981) (105)
Noradrenaline depletion exacerbates MPTP-induced striatal dopamine loss in mice. (1993) (98)
Regional distribution of [3H]imipramine binding in rat brain (1981) (94)
Serotonin autoreceptor subsensitivity and antidepressant activity. (1990) (92)
High-affinity [3H] DMI binding is associated with neuronal noradrenaline uptake in the periphery and the central nervous system. (1981) (87)
Neuropharmacology of 5-hydroxytryptamine1B/D receptor ligands. (1994) (86)
Effects of acute and repeated administration of citalopram on extracellular levels of serotonin in rat brain. (1996) (85)
gamma-Aminobutyric acid (GABA) receptor stimulation. II. Specificity of progabide (SL 76002) and SL 75102 for the GABA receptor. (1982) (84)
High-affinity 3H-imipramine binding: a new biological tool for studies in depression (1981) (83)
Clinical experience with dual action antidepressants in different chronic pain syndromes (2004) (82)
Concomitant decrease in [3H]imipramine binding in cat brain and platelets after chronic treatment with imipramine. (1982) (79)
Noradrenergic mechanisms in Parkinson's disease. (1993) (76)
The role and histological classification of needle core biopsy in comparison with fine needle aspiration cytology in the preoperative assessment of impalpable breast lesions (2001) (76)
Preclinical pharmacology of milnacipran (1996) (75)
Review: Problems associated with long-term treatment with selective serotonin reuptake inhibitors (2009) (73)
Efficacy and tolerability of milnacipran: an overview (1996) (72)
Effect of serotonergic lesion on “anxious” behaviour measured in the elevated plus-maze test in the rat (2005) (71)
Effects of four non-cholinergic cognitive enhancers in comparison with tacrine and galanthamine on scopolamine-induced amnesia in rats (2005) (64)
Effect of antidepressant drugs on monoamine synthesis in brain in vivo (1992) (62)
Two binding sites for 3H-spiroperidol on rat striatal membranes. (1978) (61)
European Society of Gastrointestinal and Abdominal Radiology (ESGAR) (2002) (56)
Effects of Milnacipran and Pindolol on Extracellular Noradrenaline and Serotonin Levels in Guinea Pig Hypothalamus (1997) (55)
The noradrenergic symptom cluster: clinical expression and neuropharmacology (2011) (53)
High-affinity 3H-imipramine binding: a new biological marker in depression. (1982) (50)
1-Aryl-2-(aminomethyl)cyclopropanecarboxylic acid derivatives. A new series of potential antidepressants. (1987) (49)
The role of transvaginal ultrasound in the investigation of women with post-menopausal bleeding. (1998) (48)
New concepts in depression (1988) (47)
Association of xanthine oxidase with the bovine milk-fat-globule membrane. (1974) (47)
Recovery of some functional properties of the detergent-extracted cholinergic receptor protein from Torpedo marmorata after reintegration into a membrane environment. (1978) (46)
Antidepressant Therapy at the Dawn of the Third Millennium (1999) (43)
Pharmacodynamics of milnacipran in young and elderly volunteers. (2002) (43)
Effects of prolonged administration of milnacipran, a new antidepressant, on receptors and monoamine uptake in the brain of the rat (1992) (42)
The effects of chemical sympathectomy with 6-hydroxydopamine on alpha-adrenoceptor and muscarinic cholinoceptor binding in rat heart ventricle. (1979) (41)
Platelet 3H-paroxetine binding to the serotonin transporter is insensitive to changes in central serotonergic innervation in the rat (1991) (40)
Association of xanthine oxidase with the bovine milk-fat-globule membrane. Nature of the enzyme-membrane association. (1975) (40)
Sedation, an unpleasant, undesirable and potentially dangerous side‐effect of many psychotropic drugs (2004) (39)
5-HT autoreceptors in the regulation of 5-HT release from guinea pig raphe nucleus and hypothalamus (1997) (39)
[3H]-Imipramine binding in human platelets: A new biochemical parameter in depression (1980) (39)
Sodium dependency of [3H]imipramine binding in rat cerebral cortex. (1981) (39)
The roles of pregn-5-ene-3β,20α-diol and 20α-hydroxy steroid dehydrogenase in the control of progesterone synthesis preceding parturition and lactogenesis in the rat (1970) (38)
Antidepressants in the treatment of fibromyalgia (2006) (38)
New hope in the treatment of painful symptoms in depression. (2003) (38)
Resolution of sexual dysfunction during acute treatment of major depression with milnacipran (2008) (37)
Specific 3H-imipramine binding in human platelets (1980) (37)
Fibromyalgia: a complex syndrome requiring a multidisciplinary approach (2009) (35)
Isolation and purification of the nicotinic acetylcholine receptor and its functional reconstitution into a membrane environment. (1977) (35)
Milnacipran, a new specific serotonin and noradrenaline reuptake inhibitor. (1998) (30)
The unique effect of methiothepin on the terminal serotonin autoreceptor in the rat hypothalamus could be an example of inverse agonism (1993) (30)
Drugs to treat fibromyalgia - the transatlantic difference. (2010) (28)
High‐ and Low‐Affinity Binding of [3H]Imipramine in Rat Hypothalamus (1986) (28)
Novel [2-(4-piperidinyl)ethyl](thio)ureas: synthesis and antiacetylcholinesterase activity. (1994) (28)
Stereoselective inhibition of 3H-imipramine binding by antidepressant drugs and their derivatives. (1980) (27)
Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors (2010) (27)
Specific serotonin and noradrenaline reuptake inhibitors (SNRIs). A review of their pharmacology, clinical efficacy and tolerability (1998) (26)
Sensitivity of the response of 5-HT autoreceptors to drugs modifying synaptic availability of 5-HT (1988) (25)
3H-Imipramine binding and serotonin uptake in platelets from untreated depressed patients and control volunteers (2004) (25)
Neuroleptic binding and their effects on the spontaneous and potassium-evoked release of 3H-dopamine from the striatum and of 3H-noradrenaline from the cerebral cortex. (1978) (24)
Regulation of neurotransmission through presynaptic receptors and other mechanisms: possible clinical relevance and therapeutic potential. (1980) (23)
Treatment of Comorbid Pain with Serotonin Norepinephrine Reuptake Inhibitors (2008) (23)
Psychopharmacology of midalcipran, 1-phenyl-1-diethyl-amino-carbonyl-2-aminomethylcyclopropane hydrochloride (F 2207), a new potential antidepressant (2004) (23)
Monoamine uptake inhibition by plasma from healthy volunteers after single oral doses of the antidepressant milnacipran (2004) (21)
Short-term surgical denervation increases 3H-clonidine binding in rat salivary gland. (1980) (21)
The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze (2005) (20)
5-HT and antidepressants: in vitro and in vivo release studies. (1993) (20)
The "forgotten" amino acid pyroglutamate. (1988) (19)
Serotonin in anxiety: evidence from animal models (1991) (19)
3H-imipramine binding in neuronal and glial fractions of horse striatum. (1980) (19)
Biochemical strategies in the search for cognition enhancers. (1990) (18)
NIH consensus conference. Diagnosis and treatment of depression in late life. (1992) (17)
High-affinity 3H-imipramine binding in platelets from untreated and treated depressed patients compared to healthy volunteers (2004) (17)
Lack of Effect of Repeated Administration of Milnacipran, a Double Noradrenaline and Serotonin Reuptake Inhibitor, on the β-adrenoceptor-linked Adenylate Cyclase System in the Rat Cerebral Cortex (1996) (17)
Evidence for a Surface Protein Layer on the Saccharomyces cerevisiae Ascospore (1970) (17)
Antidepressant Properties of Specific Serotonin—Noradrenaline Reuptake Inhibitors (1997) (17)
The Role of Serotonin in Anxiety: Behavioural Approaches (1991) (16)
Functional Neuropharmacology of Compounds Acting at 5-HT1B/D Receptors (2000) (16)
Dihydroergocristine-induced stimulation of the 5-HT autoreceptor in the hypothalamus of the rat (1986) (16)
Effect of milnacdpran and desipramine on noradrenergic α 2-autoreceptor sensitivity (1994) (14)
Benzodiazepine agonist-type activity of raubasine, a rauwolfia serpentina alkaloid. (1984) (13)
EVIDENCE AGAINST β‐ADRENOCEPTOR BLOCKING ACTIVITY OF DILTIAZEM, A DRUG WITH CALCIUM ANTAGONIST PROPERTIES (1980) (12)
Muscarinic receptor plasticity in rats lesioned in the nucleus basalis of Meynert (1989) (12)
Scopolamine induces up-regulation of nicotinic receptors in intact brain but not in nucleus basalis lesioned rats (1988) (12)
Ex vivo inhibitory effect of the 5-HT uptake blocker citalopram on 5-HT synthesis (2005) (11)
Flexible 1-[(2-aminoethoxy)alkyl]-3-ar(o)yl(thio)ureas as novel acetylcholinesterase inhibitors. Synthesis and biochemical evaluation. (1995) (11)
New concepts in Alzheimer's disease (1986) (11)
Specific 3 H-Imipramine Binding in Human Platelets Influence of Age and Sex (10)
Present and future anxiolytics. (2000) (10)
Milnacipran, a Well-Tolerated Specific Serotonin and Norepinephrine Reuptake Inhibiting Antidepressant (1998) (10)
Chronic Antidepressant Administration and Changes in 3H-imipramine Binding and Brain Receptors (1982) (10)
The roles of pregn-5-ene-3 beta, 20 alpha-diol and 20 alpha-hydroxy steroid dehydrogenase in the control of progesterone synthesis preceding parturition and lactogenesis in the rat. (1970) (10)
Indirect dopaminergic effects of tofisopam, a 2,3‐benzodiazepine, and their inhibition by lithium (1985) (9)
Fibromyalgia syndrome: an overview of potential drug targets. (2003) (9)
Neuropharmacology of a new potential anxiolytic compound, F 2692, 1-(3′-trifluoromethyl phenyl) 1, 4-dihydro 3-amino 4-oxo 6-methyl pyridazine (2005) (9)
Specific labelling of postsynaptic alpha 1 adrenoceptors in rat heart ventricle by 3H-WB 4101. (1979) (9)
3H-Rauwolscine binding in platelets from depressed patients and healthy volunteers (2004) (8)
IS ANXIETY ASSOCIATED WITH A HYPER- OR HYPO-SEROTONERGIC STATE? (1992) (8)
Specific labelling of postsynaptic α1 adrenoceptors in rat heart ventricle by 3H-WB 4101 (1979) (7)
Biochemical models for cognition enhancers. (1990) (7)
Autoradiographic characterization of binding sites for [3H]milnacipran, a new antidepressant drug, and their relationship to the serotonin transporter in rat brain (1994) (7)
Is Down-regulation of β-Adrenoceptors Necessary for Antidepressant Activity? (1988) (7)
In vitro and in vivo activity of 1-(1-naphthyl)piperazine at terminal 5-HT autoreceptors in guinea-pig brain (1995) (6)
Repeated administration of milnacipran, a new antidepressant, has no effect on a functional β-adrenergic response in the rat brain (1990) (6)
Effect of milnacipran and desipramine on noradrenergic alpha 2-autoreceptor sensitivity. (1994) (6)
Milnacipran: recent findings in depression (2010) (6)
Neuropharmacology of a new potential anxiolytic compound, F 2692, 1-(3′-trifluoromethyl phenyl) 1, 4-dihydro 3-amino 4-oxo 6-methyl pyridazine (2005) (5)
Does 5-carboxamidotryptamine-induced turning in guinea-pigs involve 5-HT1D autoreceptors? (1993) (5)
Modulation by drugs of the release of total tritium and 3H-5-HT from rat hypothalamic slices (1990) (5)
Noradrenergic symptom cluster in depression (2011) (5)
SUBSENSITIVITY OF STRIATAL DOPAMINE TARGET CELLS AFTER REPEATED TREATMENT WITH APOMORPHINE DIPIVALOYL ESTER (1979) (5)
Catecholamine and 5-HT synthesis ex vivo as an index of in-vivo neuronal activity and regulation. (1988) (5)
5-HT: on the psychiatrist's couch. (1992) (5)
ADRENERGIC RECEPTOR MECHANISMS IN THE CENTRAL NERVOUS SYSTEM IN RELATION TO CATECHOLAMINE NEURONS (1980) (5)
Brain penetration of orally administered sodium pyroglutamate (1988) (5)
Identification of 5-hydroxytryptamine1D binding sites in sheep caudate nucleus membranes. (1993) (4)
Effects of scopolamine treatment and lesion of the nucleus basalis upon various cholinergic markers in the rat brain cortex (1989) (4)
Imlink and continuing medical education: the use of an image transfer system to broadcast teaching cases nationally. (1994) (4)
The management of depression: An international naturalistic survey (2008) (4)
Binding studies on alpha-adrenoceptors and muscarinic cholinoceptors in rat heart ventricle: effect of chemical sympathectomy [proceedings]. (1979) (4)
In vivo [3H]ketanserin binding: effect of modifying synaptic serotonin levels (1988) (4)
Effect of mefenorex on 5-HT release: Studies in vitro on rat hypothalamic slices and in vivo by microdialysis (1995) (4)
Novel (2‐(4‐Piperidinyl)ethyl)(thio)ureas: Synthesis and Antiacetylcholinesterase Activity. (1994) (4)
Improving the sensitivity of stereotactic core biopsy to diagnose ductal carcinoma in situ of the breast: a mathematical model. (2001) (4)
Alteration in Brain Receptors in Affective Disorders (1981) (4)
Sodium shift of the inhibition of tritium labeled imipramine binding by 5 hydroxy tryptamine and 5 hydroxy tryptamine uptake blockers but not by tri cyclic anti depressants (1982) (3)
Where are the new therapies for anxiety and obsessive-compulsive disorders? (2001) (3)
3H-WB 4101 binding in the rat vas deferens (1981) (3)
Involvement of both α 1 - and β-Adrenoceptors in the Antagonism of Tetrabenazine-induced Effects by Antidepressants (1988) (3)
Chronic sympathetic denervation increases muscarinic cholinoceptor binding in the rat submaxillary gland (1980) (3)
Carnitine acetyltransferase activity is not changed with age in rat brain and human platelets (1990) (3)
P.1.024 Milnacipran, a double noradrenaline and 5-HT reuptake inhibiting antidepressant increases cerebral extracellular monoamine levels (1996) (3)
High-affinity binding of 3H-imipramine in brain and platelets: relevance to depression and antidepressant drugs. (1982) (2)
Behavioral changes in mice after acute and chronic imipramine or milnacipran treatment (1990) (2)
Effects of Repeated Administration of Diazepam to Rats on Locomotor Activity, Elevated Plus-maze and Various Brain Receptors (1991) (2)
Potency ratio for the inhibition of 3H-QNB and 3H-cis-methyldioxolane binding predicts agonist or antagonist activity on muscarinic receptors. (1988) (2)
Anticonvulsant Effect of Some Anxiolytic Drugs on Two Models of Sound-induced Seizures in Mice (1991) (2)
Why psychiatrists should not ignore pain in their patients—focus on fibromyalgia? (2009) (2)
Japanese experience with milnacipran, the first serotonin and norepinephrine reuptake inhibitor in Japan (2007) (2)
The effects of raubasine and dihydroergocristine on an age‐related deficit in passive avoidance learning in rats (1990) (2)
Modulation of 5-HT Autoreceptors Probably Contributes to the Antidepressant Action of 5-HT Uptake Blockers (1988) (2)
5-HT1B/1D Receptors in Psychiatry and Neurology (1998) (2)
From Dirty Drugs to Hyperselectivity and Part Way Back Again (1997) (2)
1‐Aryl‐2‐(aminomethyl)cyclopropanecarboxylic Acid Derivatives. A New Series of Potential Antidepressants. (1987) (1)
In Search of Possible Markers and Models in Alzheimer’s Disease (1986) (1)
Identification by differential pulse voltammetry of a 5-hydroxyindoleamine oxidation peak in the striatum and frontal cortex of the anaesthetized rat (1)
Long-term treatment of depression (1998) (1)
Effect of Anxiolytic and Hypnotic Drugs on Sleep Circadian Rhythms in the Rat (1991) (1)
Five years experience of prescribing milnacipran: An interview with Didier Papeta (Head of Psychiatry, General Military Hospital, Brest, France) (2003) (1)
Specific [3H]-imipramine binding in rat brain [proceedings]. (1979) (1)
P-23 Pharmacokinetic-pharmacadynamic relationship of milnacipran on platelet uptake model (1996) (1)
The Role of Noradrenaline in Depression and its Therapy (1997) (1)
An unexpected twist (1993) (1)
Diagnosis and treatment of depression in late life (1999) (1)
Is Full Recovery from Depression Possible: pocketbook (1998) (1)
[3H-Imipramine binding to human platelets. A peripheral index in depressive syndromes (author's transl)]. (1982) (0)
Use of Efaxoran and derivatives thereof for the preparation of medicaments intended for the treatment of neurodegenerative sygdo (1994) (0)
Case of the month: an unexpected twist. (1993) (0)
Serotonin transmission in depression and anxiety disorders - new insights and potential new drugs (1998) (0)
Pasteur Euroconference on future therapies for an anxious world. (1998) (0)
Abbreviating the individualized ivu is it worthwhile (1990) (0)
2063 – ALLOSTERIC INTERACTIONS OF GABA RECEPTOR AGONISTS AND ANTAGONISTS WITH THE BENZODIAZEPINE RECEPTOR (1978) (0)
Announcements (2009) (0)
Anticonvulsive properties of F1933 (dulozafone) on kindled seizures in the rat. (1990) (0)
News arylpiperazines indole derivatives, their preparation and their therapeutic use. (1993) (0)
Arylalcoyloxymethyl-2 morpholines, their preparation and their application as medicaments in the treatment of central nervous system disorder (1984) (0)
How common is poor outcome in depression (1998) (0)
New benzodioxanes and 1- (2h) -benzopyrannes, their preparation and their use as medicine (1996) (0)
AUTOREGULATION OF NORADRENALINE RELEASE AND ANTIDEPRESSANT ACTIVITY. (1992) (0)
The green evolution of psychotropic drugs. (2002) (0)
Alzheimer's disease from different angles: International Symposium on New Concepts in Alzheimer's Disease, 1–4 October 1985, Castres, France (1986) (0)
Overview: pharmacogenomics of psychiatric disorders--separating the dreams from the realities. (2001) (0)
Re: Surgeon-controlled ultrasound-guided core biopsies in the breast-a prospective study and a new use for surgeons in the clinic. (2003) (0)
5-HT1D AUTORECEPTORS IN THE ACTION OF ANTIDEPRESSANT DRUGS (1994) (0)
3H-SPIROPERIDOL BINDING IN THE RAT STRIATUM: EVIDENCE FOR THE PRESENCE OF TWO BINDING SITES (1979) (0)
What constitutes ‘recovery’ from depression? (1998) (0)
S.21.05 Milnacipran, a double noradrenaline and serotonin reuptake inhibiting antidepressant (1996) (0)
Neurochemical and Behavioral Effects Related to 5-HT1B/1D Receptors (1998) (0)
Pretreatment by DSP 4 Fails to Reduce the Effectiveness of Desipramine in Blocking Tetrabenazine-induced Ptosis or Hypothermia (1988) (0)
[Monoaminergic receptors and hypotheses of the mechanisms of action of 2nd generation antidepressive agents]. (1991) (0)
The use of efaroxan and derivatives thereof for the manufacture of a medicament for the treatment of Parkinson's disease (1994) (0)
P.1.023 Synergistic increases of noradrenaline and 5-HT neurotransmission induced by milnacipran with pindolo (1996) (0)
Can transvaginal ultrasound scanning in post menopausal women reduce the need for endometrial biopsy (1996) (0)
Group report 6 : biochemical models for cognition enhencers (1990) (0)
P-5 Milnacipran, a new well-balanced double noradrenaline and serotonin reuptake inhibitor: Biochemical and pharmacological characteristics. (1996) (0)
News imidazolidinone, pyrimidinones and 1,3-diazepin-2 -one, their preparation and their applications in therapeutics (1996) (0)
Nouveaux derives de la piperidine substitues en position 4 par un groupe imidazolidin-2-on-1-yl-ethyl, tetrahydropyrimidin-2-on-1-yl-ethyl, et 1,3-dia-zepin-2-on-1-yl-ethyl, et leurs applications comme antagonistes des recepteurs alpha-2 adrenergiques (1997) (0)
2-substituted 5-monoaryl-as-3-triazinones, process for their preparation and application thereof as medicinal agents (1987) (0)
Use of milnacipran and its derivatives for the preparation of a medicament for the treatment of certain psychiatric disorders (1997) (0)
When is a breast lump a lump? How good are general practitioners (GP) in their diagnosis, and how good are Breast Surgeons? (2001) (0)
The economic impact of recurrent depression (1998) (0)
Factors affecting outcome of depression (1998) (0)
Elevated plus maze activity and serotonergic neurotransmission in Fawn-Hooded rats (1994) (0)
Use of idazoxan and its derivatives for the preparation of a medicament for the treatment of Parkinson's disease and its development. (1992) (0)
Flexible 1-((2-Aminoethoxy)alkyl)-3-ar(o)yl(thio)ureas as Novel Acetylcholinesterase Inhibitors. Synthesis and Biochemical Evaluation. (1995) (0)
New concepts in anxiety (1990) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Michael S. Briley?

Michael S. Briley is affiliated with the following schools:

University of Bath

Michael S. Briley's Academic­Influence.com Rankings

Michael S. Briley's Degrees

Why Is Michael S. Briley Influential?

Michael S. Briley's Published Works

Published Works

What Schools Are Affiliated With Michael S. Briley?

Michael S. Briley's AcademicInfluence.com Rankings